On August 11, 2022, the Food and Drug Administration granted accelerated approval to T-DXd for NSCLC patients with activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy, representing the first drug approved for HER2-mutant NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.